Net Income (Loss) Attributable to Parent in USD of Tempest Therapeutics, Inc. from Q2 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tempest Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2011 to Q3 2025.
  • Tempest Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$3.51M, a 66.7% increase year-over-year.
  • Tempest Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$36.1M, a 1.51% decline year-over-year.
  • Tempest Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$41.8M, a 41.9% decline from 2023.
  • Tempest Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.5M, a 17.4% increase from 2022.
  • Tempest Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$35.7M, a 26.2% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Tempest Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$36.1M -$3.51M +$7.05M +66.7% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$43.1M -$7.87M +$1.7M +17.8% 01 Apr 2025 30 Jun 2025 10-Q 05 Nov 2025
Q1 2025 -$44.8M -$10.9M -$2.96M -37.4% 01 Jan 2025 31 Mar 2025 10-Q 05 Nov 2025
Q4 2024 -$41.8M -$13.8M -$6.33M -84.5% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025
Q3 2024 -$35.5M -$10.6M -$3.77M -55.6% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$31.7M -$9.57M -$1.99M -26.2% 01 Apr 2024 30 Jun 2024 10-Q 05 Nov 2025
Q1 2024 -$29.8M -$7.9M -$268K -3.51% 01 Jan 2024 31 Mar 2024 10-Q 05 Nov 2025
Q4 2023 -$29.5M -$7.49M +$1.62M +17.7% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025
Q3 2023 -$31.1M -$6.79M +$2.16M +24.2% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 -$33.3M -$7.58M +$1.59M +17.3% 01 Apr 2023 30 Jun 2023 10-Q 12 Nov 2024
Q1 2023 -$34.9M -$7.64M +$855K +10.1% 01 Jan 2023 31 Mar 2023 10-Q 12 Nov 2024
Q4 2022 -$35.7M -$9.1M +$19.2M +67.8% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024
Q3 2022 -$54.9M -$8.95M -$837K -10.3% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$54.1M -$9.17M -$2.11M -29.9% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$52M -$8.49M -$3.14M -58.6% 01 Jan 2022 31 Mar 2022 10-Q 08 Nov 2023
Q4 2021 -$48.8M -$28.3M -$31.8M -920% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2022
Q3 2021 -$17.1M -$8.11M -$2.68M -49.3% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022
Q2 2021 -$14.4M -$7.06M -$1.83M -35% 01 Apr 2021 30 Jun 2021 10-Q 08 Nov 2022
Q1 2021 -$12.6M -$5.36M +$6.64M +55.4% 01 Jan 2021 31 Mar 2021 10-Q 08 Nov 2022
Q4 2020 -$19.2M $3.45M +$16.1M 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2022
Q3 2020 -$35.4M -$5.43M +$6.2M +53.3% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 -$41.6M -$5.23M +$4.64M +47% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$46.2M -$12M -$1.63M -15.7% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021
Q4 2019 -$44.6M -$12.7M -$2.15M -20.4% 01 Oct 2019 31 Dec 2019 10-K 29 Mar 2021
Q3 2019 -$42.4M -$11.6M -$4.1M -54.4% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020
Q2 2019 -$38.3M -$9.87M -$5.03M -104% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020
Q1 2019 -$33.3M -$10.4M -$6.11M -143% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020
Q4 2018 -$27.2M -$10.5M +$31.6M +75% 01 Oct 2018 31 Dec 2018 10-K 11 Mar 2020
Q3 2018 -$58.8M -$7.54M +$1.83M +19.5% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q2 2018 -$60.6M -$4.85M +$13.3M +73.4% 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019
Q1 2018 -$73.9M -$4.26M +$10.6M +71.4% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q4 2017 -$84.6M -$42.1M -$19.5M -86.1% 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019
Q3 2017 -$65.1M -$9.37M +$9.92M +51.4% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 -$75M -$18.2M +$382K +2.06% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$75.4M -$14.9M +$6.86M +31.5% 01 Jan 2017 31 Mar 2017 10-Q 03 May 2018
Q4 2016 -$82.3M -$22.6M -$2.04M -9.91% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2018
Q3 2016 -$80.2M -$19.3M -$1.37M -7.64% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017
Q2 2016 -$78.8M -$18.6M -$1.08M -6.16% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017
Q1 2016 -$77.8M -$21.8M -$4.55M -26.5% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017
Q4 2015 -$73.2M -$20.6M -$1.71M -9.06% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2018
Q3 2015 -$71.5M -$17.9M -$5M -38.7% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016
Q2 2015 -$66.5M -$17.5M -$7.6M -76.8% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 -$58.9M -$17.2M -$9.39M -120% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016
Q4 2014 -$49.5M -$18.9M -$7.89M -71.7% 01 Oct 2014 31 Dec 2014 10-K 02 Mar 2017
Q3 2014 -$41.6M -$12.9M -$6.03M -87.5% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015
Q2 2014 -$35.6M -$9.89M -$3.9M -65% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015
Q1 2014 -$31.7M -$7.81M -$2.66M -51.5% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015
Q4 2013 -$29M -$11M -$6.81M -162% 01 Oct 2013 31 Dec 2013 10-K 26 Feb 2016
Q3 2013 -$22.2M -$6.89M -$3.77M -121% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014
Q2 2013 -$18.5M -$6M -$2.76M -85.4% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$15.7M -$5.16M -$2.19M -73.9% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014
Q4 2012 -$13.5M -$4.19M 01 Oct 2012 31 Dec 2012 10-K 16 Mar 2015
Q3 2012 -$3.12M -$2.34M -303% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013
Q2 2012 -$3.23M -$2.82M -689% 01 Apr 2012 30 Jun 2012 10-Q 13 Aug 2013
Q1 2012 -$2.97M 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013
Q3 2011 -$774K 01 Jul 2011 30 Sep 2011 10-Q 13 Nov 2012
Q2 2011 -$410K 06 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012

Tempest Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$41.8M -$12.4M -41.9% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$29.5M +$6.22M +17.4% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 -$35.7M -$7.41M -26.2% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 -$28.3M -$9.09M -47.3% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
2020 -$19.2M +$25.4M +56.9% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022
2019 -$44.6M -$17.4M -63.9% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2021
2018 -$27.2M +$57.4M +67.9% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020
2017 -$84.6M -$2.32M -2.82% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019
2016 -$82.3M -$9.04M -12.3% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2018
2015 -$73.2M -$23.7M -47.9% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018
2014 -$49.5M -$20.5M -70.5% 01 Jan 2014 31 Dec 2014 10-K 02 Mar 2017
2013 -$29M -$15.5M -115% 01 Jan 2013 31 Dec 2013 10-K 26 Feb 2016
2012 -$13.5M 01 Jan 2012 31 Dec 2012 10-K 16 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.